Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2026
Reporting Period: Event-based report for September 22, 2026.
Business Overview: The company is a Delaware corporation focused on noninvasive lung cancer diagnostics, specifically its CyPath® Lung technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K reports a corporate event rather than financial results.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document details a strategic update regarding the presentation of clinical research.
Outlook, Management Commentary, and Risks
- Event: The company announced it is presenting two posters at the 2026 NAVREF Annual Conference (September 27-30, 2026, in Arlington, Virginia).
- Subject Matter: The presentations highlight the CyPath® Lung diagnostic in clinical practice and ongoing research evaluating the technology in veteran and military populations.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) but does not contain direct management commentary on financial outlook or specific risks within the body of the 8-K text.
Key Facts for Investor Verification
- Verify the content and findings of the two posters presented at the 2026 NAVREF Annual Conference regarding CyPath® Lung.
- Review the attached press release (Exhibit 99.1) for detailed data on the veteran and military population research.
- Confirm the company's status as an emerging growth company (indicated as yes in the filing).
- Note that this filing contains no financial data; investors should refer to the most recent 10-Q or 10-K for financial metrics.